Avalo Therapeutics AVTX Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's available-for-sale debt securities - unrealized loss position (<12 months)?
- Avalo Therapeutics (AVTX) reported available-for-sale debt securities - unrealized loss position (<12 months) of $54.7M in Q1 2026.